Immune disorders are a leading cause of morbidity and long-term health challenges among children worldwide. Recent decades ...

Use of JenaValve in a Young Female With Severe Aortic Regurgitation and Takayasu Arteritis ...

AbbVie’s Rinvoq (upadacitinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with giant cell arteritis (GCA), or temporal arteritis, an autoimmune disease of medium ...

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus, and vitiligo. 5-9 ...

Takayasu's arteritis is a rare inflammatory disease that affects the arteries. Explore the symptoms, causes, diagnosis, treatment options, and how to manage this condition effectively.

It is being studied in late-stage studies for some others like alopecia areata, systemic lupus erythematosus, hidradenitis suppurativa vitiligo and Takayasu arteritis.

European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.

Upadacitinib (Rinvoq) is being studied in phase 3 clinical trials for alopecia areata, giant cell arteritis, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus and vitiligo.

Takayasu arteritis is a rare, chronic inflammatory disease that primarily affects the aorta and its main branches. It is a form of vasculitis. Learn more here.

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for alopecia areata, giant cell arteritis, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus, and vitiligo. 8 ...

Ellie Suggett, from Ormesby, was diagnosed with Takayasu's Arteritis after a visit to A&E ...